Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

@article{Bent2009RandomizedPI,
  title={Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.},
  author={Martin J. van den Bent and Alba A Brandes and Roy Rampling and Mathilde C. M. Kouwenhoven and Johan M. Kros and Antoine F Carpentier and Paul M. J. Clement and Marc Paul Frenay and Mario Campone and J Baurain and J Armand and Martin J. B. Taphoorn and Alicia Tosoni and Heidemarie Kletzl and Barbara Klughammer and Denis Lacombe and Thierry Gorlia},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 8},
  pages={1268-74}
}
PURPOSE Approximately 50% of glioblastomas (GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In approximately 25% of instances, constitutively activated EGFR mutants are present. These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM. PATIENTS AND METHODS In a randomized, controlled, phase II trial, 110 patients with progressive GBM after prior radiotherapy were randomly assigned to… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
201 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 201 extracted citations

Similar Papers

Loading similar papers…